Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors : Current Status and Future Directions by Bauer, Sebastian & Joensuu, Heikki
LEADING ARTICLE
Emerging Agents for the Treatment of Advanced, Imatinib-
Resistant Gastrointestinal Stromal Tumors: Current Status
and Future Directions
Sebastian Bauer1,2 • Heikki Joensuu3
Published online: 18 July 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Imatinib is strongly positioned as the recom-
mended first-line agent for most patients with advanced
gastrointestinal stromal tumor (GIST) due to its good
efficacy and tolerability. Imatinib-resistant advanced GIST
continues to pose a therapeutic challenge, likely due to the
frequent presence of multiple mutations that confer drug
resistance. Sunitinib and regorafenib are approved as sec-
ond- and third-line agents, respectively, for patients whose
GIST does not respond to imatinib or who do not tolerate
imatinib, and their use is supported by large randomized
trials. ATP-mimetic tyrosine kinase inhibitors provide
clinical benefit even in heavily pretreated GIST suggesting
that oncogenic dependency on KIT frequently persists.
Several potentially useful tyrosine kinase inhibitors with
distinct inhibitory profiles against both KIT ATP-binding
domain and activation loop mutations have not yet been
fully evaluated. Agents that have been found promising in
preclinical models and early clinical trials include small
molecule KIT and PDGFRA mutation-specific inhibitors,
heat shock protein inhibitors, histone deacetylase inhibi-
tors, allosteric KIT inhibitors, KIT and PDGFRA signaling
pathway inhibitors, and immunological approaches
including antibody-drug conjugates. Concomitant or
sequential administration of tyrosine kinase inhibitors with
KIT signaling pathway inhibitors require further evalua-
tion, as well as rotation of tyrosine kinase inhibitors as a
means to suppress drug-resistant cell clones.
Key Points
Mutated KIT kinases that confer drug resistance
emerge frequently in patients with advanced GIST
treated with imatinib.
Besides ATP-mimetic tyrosine kinase inhibitors
many other agents with a different mechanism of
action are efficacious in the treatment of patients
with advanced GIST.
Concomitant or sequential administration of agents
with different mechanisms of action may become a
novel approach to treat advanced GIST.
1 Introduction
Gastrointestinal stromal tumor (GIST) is one of the most
common types of sarcoma [1]. Small (\1 cm) GISTs
(‘‘micro-GISTs’’) are highly prevalent (*20 %) in the
general population aged over 50 years [2, 3], but these
lesions have little or no malignant potential. Excluding
micro-GISTs, the annual incidence of GIST is about
1/100,000. Approximately 40 % of patients will eventually
have metastases after macroscopically complete surgery
[4]. The median overall survival for patients with
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metastatic GIST was 12–18 months before the introduction
of imatinib [5].
Approximately 90 % of metastatic GISTs harbor an
activating mutation in the genes that encode KIT or pla-
telet-derived growth factor-a (PDGFRA) receptor tyrosine
kinases [6, 7]. Mutations are usually located in KIT exon 11
(*70 %), KIT exon 9 (*10 %), or PDGFRA exons 12 or
18 (*10 %). Mutations in other exons are infrequent in
patients who have not been treated with tyrosine kinase
inhibitors (TKIs) [8], and 5–10 % of GISTs do not harbor
KIT or PDGFRA mutation (frequently referred to as ‘‘wild-
type GISTs’’).
Conventional chemotherapy agents have little activity
against GIST. During the past 15 years TKIs have trans-
formed the treatment landscape in an unprecedented way.
Several TKIs yield durable responses in patients with
advanced GIST, and adjuvant imatinib improves recur-
rence-free survival [9, 10] and likely overall survival [10]
when administered to GIST patients after surgery.
Although the treatment of GIST with TKIs is one of the
most compelling success stories in the recent history of
medicine, a major challenge is the eventual emergence of
drug resistance in advanced GIST. We review here the
experimental agents studied to treat imatinib-resistant
advanced GIST.
2 Approved Agents
2.1 Imatinib
Imatinib has been considered the standard first-line agent
since its approval in 2002. It is an inhibitor of a few kinases
including KIT, PDGFRA, ABL, Fms-like tyrosine kinase-3
(FLT3), and colony stimulating factor-1 receptor (CSF1R),
and yields durable responses or stabilized disease (SD) in
approximately 85 % of the patients [11, 12].
Two randomized phase III trials that compared an
imatinib daily dose of 400 to 800 mg identified the 400-mg
dose as the standard dose for patients with a KIT exon 11
mutation [13, 14]. In a retrospective subgroup analysis,
patients with a KIT exon 9 mutation had longer progres-
sion-free survival (PFS) on the 800-mg dose as compared
with the 400-mg dose [15]. PDGFRA substitution muta-
tions at codon D842 (usually D842V) lead to imatinib-
resistant mutant kinases [16]. Mutational testing for KIT
and PDGFRA is therefore considered mandatory in the
treatment planning [17].
Most patients with advanced GIST are not cured with
imatinib. The median PFS is 2–3 years [18], but a minority
remain progression-free for C10 years after starting ima-
tinib [19]. Patients are treated with continuous imatinib as
discontinuation in responding patients is usually associated
with rapid progression [20]. In one trial patients whose
GIST had progressed on at least imatinib and sunitinib
were randomly assigned to either imatinib re-challenge or
placebo. The median PFS was 1.8 months on imatinib and
0.9 months on placebo [21]. Despite survival not improv-
ing, these findings suggest a modest benefit from imatinib,
even as ‘‘last-line’’ therapy.
2.2 Sunitinib
Like imatinib, sunitinib binds to the ATP-binding pocket of
the KIT and PDGFRA kinases. Sunitinib has different
binding characteristics from imatinib and it also efficiently
inhibits the vascular endothelial growth factor receptor
(VEGFR) and RET tyrosine kinases.
Sunitinib was approved in 2006 for patients whose
GIST has progressed on imatinib or who do not tolerate
imatinib based on the results of a placebo-controlled trial
[22]. In this study with 312 patients sunitinib was
administered at a dose of 50 mg/day for 4 weeks followed
by a break of 2 weeks before the next cycle. The median
PFS was 6.3 and 1.5 months in the sunitinib and placebo
groups, respectively [hazard ratio (HR) 0.33, p\ 0.0001),
the partial response (PR) rates were 7 and 0 %, and the
rates of stabilized disease (SD) 58 and 48 %. Cross-over
to the sunitinib group was allowed, but despite this,
overall survival was superior in the sunitinib group. The
most frequent adverse effects were anemia, neutropenia,
fatigue, diarrhea, skin discoloration, nausea, and anorexia.
Sunitinib treatment is also frequently associated with
hand-foot syndrome and occasionally hypothyreosis [23].
Administration at a continuous daily dose of 37.5 mg is
considered an alternative dosing schedule [24]. Despite
these convincing results, the clinical benefits of second-
line sunitinib remain moderate as compared with the
substantial benefits obtained with imatinib in a first-line
setting.
2.3 Regorafenib
Regorafenib is an oral TKI that inhibits multiple kinases
involved in oncogenesis (KIT, PDGFRA, RET, RAF1,
BRAF), angiogenesis (VEGFR1-3, TIE2), and the tumor
microenvironment (fibroblast growth factor receptor,
FGFR). Regorafenib was approved in 2013 for the treat-
ment of GIST patients who no longer respond to imatinib
and sunitinib based on a placebo-controlled, randomized
phase III trial (GRID) [25]. In GRID, 199 such patients
were allocated to regorafenib 160 mg/day or matching
placebo (3 weeks on/1 week off) until disease progression.
The median PFS was 4.8 months on regorafenib and
0.9 months on placebo (HR 0.27, p\ 0.0001). Six (4.5 %)
and one (1.5 %) of the patients assigned to regorafenib and
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placebo had PR, respectively, and 71.4 and 33.3 % had SD.
Drug-related grade 3 adverse events were frequent in the
regorafenib group as compared to placebo (58 vs. 8 %),
with hand-foot skin reaction, hypertension, and diarrhea
being most often recorded.
Sunitinib and regorafenib have a less favorable side
effect profile compared to imatinib, which is likely asso-
ciated with their broader kinase inhibition spectrum. Hand-
foot syndrome tends to occur earlier with regorafenib than
with sunitinib and is generally more severe. Regorafenib
has significant liver toxicity, and liver function tests are
recommended before initiation of regorafenib and at least
every 2 weeks during the first 2 months on therapy [26].
The benefit of VEGFR inhibition remains undefined in
GIST.
3 Imatinib Resistance
Secondary KIT mutations are the dominant mechanism for
imatinib resistance [27, 28]. They occur frequently either in
the kinase ATP-binding domain (encoded by exons 13 and
14) or in the activation loop (a-loop, encoded by exon 17),
and typically affect the key amino acids that interact with
imatinib binding to the kinase. Mutations in the a-loop shift
the equilibrium towards the active kinase conformation,
while imatinib and sunitinib bind to the inactive confor-
mation [29].
In a mutagenesis screen of cells driven by mutant KIT
proteins, sunitinib effectively suppressed cells with KIT
exon 13 (V654A) or exon 14 resistance mutations (T670I),
but not exon 17 mutant kinases [30]. These results are
compatible with findings from a clinical trial in which
sunitinib had substantial activity against GISTs with sec-
ondary KIT exon 13 mutations [31]. In contrast, rego-
rafenib shows higher potency for KIT exon 17 mutations,
but is less potent for the ATP-binding domain affecting
mutations. Imatinib-resistant disease frequently harbors
several resistance mutations, sometimes even within a
single metastasis [28, 32, 33].
The rare alternative mechanisms that may cause ima-
tinib resistance include KIT amplification and loss of
tumor KIT expression [27]. Alternative signaling path-
ways may supplant KIT as the oncogenic driver, but have
not been confirmed in patients. Notably, dysregulation of
the phosphatidylinositide 3-kinases (PI3K)/AKT pathway
by PI3K-mutations or aberrations that cause loss of the
phosphatase and tensin homolog (PTEN) function, or
mutations of BRAF, KRAS, or HRAS that activate the
RAS/RAF/MEK pathway, have been detected in single
cases, but their overall role in drug resistance is unclear
[34, 35].
4 Investigational Agents
Many investigational agents are potent KIT and PDGFRA
inhibitors, and therefore potentially active against GIST.
4.1 ATP Mimetics
ATP mimetics are orally administered small molecule
agents that bind to the target kinase ATP-binding pocket
and compete with ATP for binding (Table 1).
4.1.1 Nilotinib
Nilotinib has been evaluated in randomized trials [36, 37]
and cohort studies [38, 39]. In a randomized study carried
out in a first-line setting, 644 patients who had received no
systemic antineoplastic therapy or who had GIST recur-
rence C6 months after discontinuing adjuvant imatinib
received either nilotinib 400 mg twice daily or imatinib
400 mg once daily [37]. Accrual was stopped early after
crossing the futility boundary, and both PFS and overall
survival significantly favored imatinib. Somewhat unex-
pectedly, patients treated with imatinib had better PFS in
the subgroup with KIT exon 9 mutation, but not among
patients with exon 11 mutation.
Nilotinib was compared to best supportive care (BSC) or
with the physician’s choice in a randomized trial with 248
patients who had progressed on imatinib and sunitinib [36].
Most control group patients received either imatinib or
sunitinib in addition to BSC. No PFS difference emerged at
a blinded central radiology review between the groups.
The development of nilotinib in the treatment of GIST
was halted based on these results, but since nilotinib is well
tolerated, it could have a niche in the treatment of patients
who do not tolerate imatinib and whose GIST harbors KIT
exon 11 mutation.
4.1.2 Masitinib
Masitinib is approved for the treatment of mastocytosis in
dogs. In a phase II trial where 30 imatinib-naı¨ve patients
received masitinib 7.5 mg/kg/day, one patient had com-
plete response (CR), 15 had PR, 13 SD, and one disease
progression as the best response, and the median PFS was
41.3 months [40]. These efficacy results resemble those
obtained with imatinib. The most frequent grade 3/4 toxi-
cities were skin rash (10 %) and neutropenia (7 %).
In a small randomized, open-label trial 23 patients who
had progressed on imatinib were assigned to 12 mg/kg/day
of masitinib and 21 comparable patients to sunitinib [41].
The median PFS was relatively short in the masitinib group
(3.7 months), but overall survival favored masitinib to
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sunitinib after allowing post-progression administration of
sunitinib in the masitinib group. Masitinib was better tol-
erated. These results warrant confirmation in the ongoing
phase III trials (NCT00812240 and NCT01694277).
4.1.3 Sorafenib
Sorafenib resembles regorafenib in structure and in the
kinome inhibition spectrum. Sorafenib is approved for the
treatment for unresectable hepatocellular carcinoma,
advanced renal cell carcinoma, and differentiated thyroid
cancer. In vitro, sorafenib inhibits imatinib-resistant kina-
ses with mutations in the KIT ATP-binding pocket and in
the activation loop, with the exception of kinases resulting
from substitutions at KIT codon D816 or PDGFRA codon
842 [42].
In a retrospective cohort study with 117 evaluable
patients whose GIST had progressed on imatinib and suni-
tinib, and who were treated with sorafenib 400 mg twice
daily, 12 (10 %) patients responded and 70 (60 %) had SD.
The median PFS was 6.4 months [43]. Sorafenib was
moderately well tolerated, with skin rash, hand-foot syn-
drome, and diarrhea being the most frequent adverse effects.
In another retrospective study, six (19 %) patients
responded and 14 (44 %) had SD in a cohort of 32 patients
whose GIST had progressed on imatinib, sunitinib, and
nilotinib [44]. These and further data [45] suggest that the
efficacy of sorafenib might be comparable to that of
regorafenib in the treatment GIST resistant to imatinib and
sunitinib.
4.1.4 Dovitinib
The Korean GIST group conducted a study that evaluated
dovitinib among 30 patients whose disease had progressed
at least on imatinib and sunitinib, and found a disease
control rate of 13 % at 24 weeks after treatment initiation
and a median PFS of 3.6 months [46].
In another study in 38 patients who had progressed on
imatinib or who were intolerant to imatinib, two (5 %)
patients had PR with dovitinib and 16 (42 %) SD. The
median PFS was 4.6 months [47]. The most frequent grade
3 side effects were hypertension (18 %), fatigue (12 %),
vomiting (10 %), and elevated blood triglyceride and c-
glutamyltransferase levels. Dovitinib may not be superior to
sunitinib or regorafenib, but careful data evaluation might
identify subgroups of patients who benefit from dovitinib.
4.1.5 Pazopanib
Pazopanib is approved for the treatment of renal cell cancer
and soft tissue sarcomas. The IC50 value for inhibition of
wild-type KIT was 74 nM in in vitro kinase assays [48], but
little is known about its activity on KIT drug resistance
mutations.
In a phase II study 12 (48 %) out of the 25 patients
whose GIST had progressed on at least imatinib and
sunitinib had SD and the median PFS was 1.9 months [49].
The randomized phase II PAZOGIST trial compared
pazopanib plus BSC with BSC alone among 81 patients
whose GIST was resistant to imatinib and sunitinib, or who
did not tolerate these agents [50]. The 4-month PFS rate
favored pazopanib plus BSC over BSC alone (45 vs. 18 %,
respectively; p = 0.03). Of the 76 patients who were treated
with pazopanib (including 36 patients who crossed over
fromBSC to pazopanib after progression), 72 % hadCgrade
3 adverse events (37 % had hypertension). These data do not
suggest a higher activity as compared with regorafenib, but
the toxicity profile of pazopanib could be more favorable.
4.1.6 Ponatinib
Ponatinib is highly active in heavily pre-treated patients for
Philadelphia-positive leukemia, and exhibits a pan-BCR-
ABL inhibitory profile in vitro with no single mutation
conferring ponatinib resistance [51]. Ponatinib is one of the
few ATP-competitive KIT-inhibitors that has been tested
against a large panel of mutant KIT variants [30]. In a
mutagenesis screen 40 nmol/L of ponatinib suppressed the
growth of all KIT secondary mutants except V654A, which
was suppressed at 80 nmol/L. Ponatinib shows high
activity against KIT exon 17 mutants, and unlike the
approved KIT inhibitors, it is active against the KIT exon
17 D816 mutant kinases [30].
The preliminary results from a non-randomized phase II
trial that evaluated ponatinib at a dose of 45 mg/day in
heavily treated GIST patients (74 % had C4 prior agents)
the clinical benefit rate (CR, PR, or SD C16 weeks) was
55 % in patients with primary KIT exon 11 mutation, but
responses were also observed with the 30-mg dose [30, 52].
The most common side effects were skin rash (54 %),
fatigue (46 %), myalgia (46 %), dry skin (40 %), and
headache (40 %). Ponatinib is only infrequently associated
with hand-foot syndrome or mucositis. No serious throm-
boembolic events were observed during the short follow-
up, but 11.8 % of the patients with BCR–ABL-driven
leukemia had serious arterial thrombotic events that accu-
mulated over a period of 24 months.
The risk of thromboembolic events may be dose-de-
pendent, and the ponatinib blood maximum concentrations
with the 15 mg/day dose and the trough concentrations
with the 30 mg/day dose exceeded the 40 nM/L concen-
tration that is required to suppress most imatinib-resistant
KIT clones [53]. A phase II trial (POETIG) will evaluate
ponatinib at a dose of 30 mg/day in patients whose GIST is
resistant to imatinib.
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4.1.7 Other Tyrosine Kinase Inhibitors
In a phase I study evaluating cabozantinib, four pretreated
Japanese patients had SD lasting for 6–20 months [54].
The CABO-GIST study (NCT02216578) aims to evaluate
cabozantinib in a larger patient cohort.
Vandetanib is approved for the treatment medullary
thyroid cancer [55]. It is being investigated in a phase II
trial in pediatric and adult patients with GIST who lack KIT
and PDGFRA mutations (NCT02015065).
Famitinib induced PR in one of the two patients with
treatment-naı¨ve GIST included in a phase I study [56], and
is being investigated as second-line treatment of advanced
GIST (NCT02336724). Side effects included hypertension,
hand-foot syndrome, mucositis, fatigue, and neuropathy.
In a phase II trial with 45 patients whose GIST was
resistant to imatinib or to both imatinib and sunitinib, two
(4 %) patients treated with vatalanib had confirmed PR and
further 16 (36 %) had SD lasting for C6 months (median
12.5 months) [57]. Vatalanib was well tolerated, with
hypertension (29 %), nausea (29 %), and dizziness (24 %)
being the most common side effects (usually grade 1 or 2).
Vatalanib is not being tested further in clinical trials.
Dasatinib is a potent inhibitor of BCR-ABL and the
SRC-family kinases, and it also inhibits KIT and the
PDGFRs [58]. Dasatinib is approved for the treatment of
chronic myeloid leukemia. In a phase II study where TKI-
naı¨ve GIST patients were treated with dasatinib 70 mg
twice daily, 31 (74 %) of the 42 eligible patients had
metabolic response in fluorodeoxyglucose (FDG)-PET
performed 4 weeks after dasatinib initiation [59]. The
median PFS of 13.6 months achieved appears short in this
setting. Adverse effects were most frequently gastroin-
testinal or pulmonary (grade 3, 48 %; grade 4, 5 %).
Similarly, in another series where all patients had imatinib-
resistant GIST and most also sunitinib-resistant disease, the
median PFS was only 2.0 months [60].
4.1.8 Mutation-Specific Inhibitor
BLU285 is a mutation-specific inhibitor of KIT D816V and
PDGFRA D842V mutated kinases that are resistant to most
TKIs. Preclinical data suggest a favorable toxicity profile,
but clinical trials are pending [61]. BLU285 has a very
narrow inhibition profile, and might therefore become a
candidate for combination trials.
4.1.9 PDGFRA-Targeted Agents
Crenolanib is an oral small-molecule inhibitor of FLT3 and
the PDGFRs (including D842V-mutated kinase) [62].
Metastatic PDGFRA-mutant GIST is exceedingly rare, and
in a phase II trial with seven patients, one had an objective
response and three had SD [63]. In a trial that accrued
leukemia patients, the most common side effects were
fatigue, nausea, and vomiting [64]. A clinical trial inves-
tigating olaratumab, an anti-PDGFRA antibody, was ter-
minated prematurely due to lack of efficacy.
4.2 Other Targeted Agents
4.2.1 Heat Shock Protein 90 (HSP90) Inhibitors
HSP90 chaperone protein stabilizes and enhances confor-
mational maturation of many proteins [65] including KIT
and PDGFRA. As ATP hydrolysis is required, HSP90
becomes pharmacologically targetable [66]. HSP90 inhi-
bition eventually results in proteasomal degradation of the
client proteins. One of the first HSP90-inhibitors, the gel-
danamycin analogue 17-AAG, inhibited KIT regardless of
the type of imatinib-resistance mutation [67]. The HSP90
co-chaperone cdc37 ranked the highest in a genome-wide
functional screen on two KIT-mutant cell lines, suggesting
that the chaperones are relevant in maintaining KIT sig-
naling [68].
Retaspimycin (IPI-504), a 17-AAG derivative, had
promising efficacy in a phase I trial [69], but a subsequent
randomized phase III trial performed in a third-line setting
was terminated early due to higher mortality in the retas-
pimycin group.
Ganetespib was generally well tolerated in a cohort of
23 GIST patients, but no responses were obtained and the
12 (52 %) SDs achieved were usually short [70]. BIIB021
was also well tolerated, but had limited clinical activity
[71].
AT13387 showed promising preclinical activity in GIST
[72], and seven GIST patients were treated in the first-in-
human phase I trial. One patient had PR lasting for 10
months, and three had SD for up to 8 months [73]. This
prompted initiation of a phase II trial in GIST
(NCT01294202), but the results are pending. Similarly, a
small molecule inhibitor, AUY922, had activity in pre-
clinical GIST models, but the results from a phase II trial
conducted in a patient population with imatinib- and suni-
tinib-resistant GIST are not yet available (NCT01404650).
4.2.2 Histone Deacetylase Inhibitors (HDACIs)
Acetylation of the lysine residues of the core histone pro-
teins leads to a relaxed chromatin structure enabling tran-
scription [74]. HDACIs have selectivity for cell cycle
inhibitory genes [75]. In addition, many non-histone pro-
teins important for oncogenesis are targets for acetylation
and deacetylation (e.g. p53) [76].
HDACI treatment results in transcriptional downregu-
lation and proteasomal degradation of KIT, and additive
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effects are found in combination with imatinib both in vitro
and in vivo [77, 78]. This prompted a phase I trial with
panobinostat, a third-generation pan-HDACI, in combina-
tion with imatinib 400 mg/day in a heavily pretreated GIST
patient population. The maximum tolerated dose in the
combination was 20 mg panobinostat given orally three
times weekly during three out of every four weeks, which
was only moderately well tolerated with substantial
hematological toxicity (thrombocytopenia) [79]. One out of
the 11 evaluable patients showed metabolic PR, seven were
metabolically stable for C3 weeks, and three progressed.
The longest treatment duration was 17 weeks. The
panobinostat administration schedule may need further
refinement, and other combinations warrant evaluation.
4.2.3 Allosteric KIT Inhibitors
In addition to the ATP-binding pocket KIT has another
pocket, an interior pocket located between the N- and
C-lobes of the kinase. There are two pendant ligands that
compete for occupancy of this ‘‘switch pocket’’ [80, 81].
Mutation or deletion of the inhibitory switch ligand renders
KIT constitutively active. Novel KIT inhibitors that target
the switch pocket were recently developed (DP-2976, DP-
3636, and DP-4444). They are highly potent against several
imatinib and sunitinib-resistant GIST cell lines [80, 82]. It
is unclear whether these compounds are candidates for
clinical trials, but the rationale for their use is strong. While
the ATP-binding pockets are highly conserved throughout
the kinome, the allosteric sites have greater structural
diversity, and compounds targeting these sites may inhibit
kinase activity with a high selectivity [80].
4.3 Inhibition of Signaling Pathways
The oncogenic KIT signaling is mainly relayed via the
PI3K/mammalian target of rapamycin (mTOR) and the
RAS/RAF/MEK/MAPK pathways in GISTs with or with-
out secondary resistance mutations, and inhibition of both
PI3K and MEK results in strong proapoptotic and
antiproliferative effects in vitro and in vivo [83–85].
Besides KIT, molecular aberrations in other key proteins
may activate these pathways, such as aberrations in PTEN,
PI3K, RAF, RAS, or NF1 [35, 86–88].
The combination of everolimus, an mTOR inhibitor, and
imatinib was one of the first combinations of targeted
agents studied in GIST [89]. When patients refractory to
imatinib or to imatinib and sunitinib were treated with
everolimus and imatinib 600–800 mg/day, the combination
was well tolerated, with diarrhea, nausea, fatigue, and
anemia as the most common adverse events. The pro-
gression-free rate was 37 % 4 months after treatment
initiation and one patient had PR, but the median PFS of
3.5 months achieved was relatively short. No follow-up
trial was initiated, but this combination might qualify for
testing with a PI3K inhibitor in imatinib-resistant disease.
Ongoing trials are investigating the combination of
imatinib plus a MEK inhibitor (MEK162/binimetinib) as
first-line treatment (NCT01991379), and imatinib plus a
PI3K inhibitor (BYL719) as third-line treatment
(NCT01735968). In a phase Ib/II trial in a heavily pre-
treated patient population, nine out of the 15 evaluable
patients treated with binimetinib plus imatinib had stable
disease at 8 weeks on treatment, and five (33 %) had a
partial response according to the Choi criteria [90].
4.4 Immunological Approaches
LOP628 is a conjugate consisting of an anti-KIT human-
ized IgG1/j antibody linked with a maytansine payload. As
this approach is based on KIT expression and not on the
type of KIT mutation, it might have efficacy not only
against GISTs refractory to TKIs but also for patients with
wild-type GIST.
In a study investigating the combination of dasatinib and
ipilimumab (NCT01643278), an antibody targeting the
immune checkpoint protein cytotoxic T-lymphocyte-asso-
ciated protein-4 (CTLA4), one out of the eight patients
treated had durable SD for 59? weeks [91]. Few data are
available about the expression of other checkpoint proteins
such as PDL1, PDL2, or LAG3 in GIST. The study eval-
uating pembrolizumab, an antibody that targets the pro-
grammed cell death 1 (PD-1) receptor, in advanced
sarcomas (NCT02406781) is not yet recruiting patients.
Some studies suggest a role for the natural killer cells in the
immune control of GIST [92, 93].
4.5 Other Targets
CDKN2A loss is a common genetic aberration in metastatic
GIST [94], and several studies show an association
between low tumor p16ink4 (the gene product of CDKN2A)
and frequent response to cyclin-dependent kinase (CDK)
4/6 inhibitors [95]. Based on such observations, one study
is investigating palbociclib (a CDK 4/6 inhibitor) in
patients whose GIST is refractory to imatinib and sunitinib
(NCT01907607).
FGFRs may mediate resistance to imatinib in GIST [96,
97]. A current trial evaluates a pan-FGFR inhibitor BGJ398
in combination with imatinib in untreated advanced GIST
(NCT02257541), but no results are yet available.
Inhibition of the mouse double minute 2 homolog
(MDM2) enhanced the pro-apoptotic effects of KIT inhi-
bitors in GIST cell lines [98]. MDM2 inhibitors are
1330 S. Bauer, H. Joensuu
currently being tested in phase I trials, but not at present in
GIST. A trial with BBI503, an orally administered multi-
kinase inhibitor with putative activity against cancer stem
cells, is being planned as the treatment for advanced GIST
(NCT02232620).
5 Future Prospects
A large tumor load is a negative prognostic factor for
overall survival [99]. Minimizing the tumor load by
metastasis surgery might postpone emergence of drug-re-
sistant mutations [100], but this hypothesis remains
unproven. Plasma DNA sequencing might help in screen-
ing for pre-existing or emerging resistant subclones.
Alternation of TKIs with different kinome inhibitory
profiles may be feasible and might suppress resistant
clones. It is important to investigate drug combinations that
include a mutation-specific inhibitor or an agent that
inhibits a KIT-depending signaling cascade, and the novel
immune function-modifying agents also warrant
investigation.
6 Conclusions
Imatinib is strongly positioned as the recommended first-
line agent for most patients with advanced GISTs because
of its good efficacy and tolerability. Use of sunitinib and
regorafenib as second- and the third-line agents, respec-
tively, is supported by large randomized trials. There are,
however, several agents that are potentially useful but have
not yet been fully evaluated, such as sorafenib, masitinib,
and ponatinib, and the novel approaches described warrant
further study. In the authors’ opinion, potentially effective
novel agents may be investigated relatively early in patient
populations with imatinib-refractory GIST, prior to treat-
ment with sunitinib or regorafenib, as sunitinib and rego-
rafenib are only moderately well tolerated and responses to
them may remain relatively short lived.
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